Notably, we found that nYAP1 expression in residual cancer cells is an independent prognostic marker for BCR in high-risk patients with PCa who underwent RP after CHT, suggesting that high levels of nYAP1 may potentially be a tissue biomarker for poor outcomes after surgery and play an important role in chemohormonal resistance in patients with PCa. This evidence concerns the gene NYAP1 and posterior cortical atrophy.